Literature DB >> 10365148

Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy.

W Schafhauser1, A Ebert, J Brod, S Petsch, K M Schrott.   

Abstract

BACKGROUND: The value of systematic lymphadenectomy has been a matter of great controversy for a long period of time. A recently published paper of a retrospective autopsy study generally doubts its therapeutic effectiveness, arguing that positive lymph nodes are nearly always associated with distant metastases. PATIENTS AND METHODS: Between 1974 and 1993 1035 patients suffering from renal cell carcinoma with stages from cT 1 to 4, cM 0 were treated with curative intention. 51% underwent radical abdominal tumour nephrectomy with systematic lymphadenectomy (n = 531, group A). In 199 patients (19%, group B) only macroscopically suspect lymph nodes were removed surgically. All other patients underwent radical lumbar tumour nephrectomy without lymphadenectomy (n = 305, 29%, group C).
RESULTS: Mean age of group A was 55.5 +/- 10 years, B 60.3 +/- 11 and C 66.5 +/- 11. Median follow-up for all groups was 115 +/- 63 months. Median amount of removed lymph nodes was 18 in group A, 6 in group B and 3 in group C. N-categories for each group were pN 1: 4%, 2%, 1%; pN 2: 7%, 5%, 1%; pN 3: 3%, 2, %, 1%; pN x: 0%, 35%, 67% respectively. Group A with systematic lymphadenectomy had the least favourable tumour stage overall. Nevertheless long-term survival of this group is more favourable with 57% +/- 6 when compared to group B with 50 +/- 12% and C with 44% +/- 9%. 20 (27%) of the 75 lymph node positive patients of group A who have been followed-up for more than 5 years are still alive.
CONCLUSIONS: At least 4% of all patients benefit from extensive lymphadenectomy. This may only be a relatively small proven effect for the entire patient collective, but for a single lymph node positive patient this is an undoubtedly significant additional chance of survival especially when one notes that presently there is no curative adjuvant therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10365148

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

Review 1.  Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Authors:  Samdeep K Mouli; Lee C Zhao; Reed A Omary; C Shad Thaxton
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

2.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

3.  Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma.

Authors:  Stephen J Freedland; Jean B Dekernion
Journal:  Rev Urol       Date:  2003

4.  Lymph node dissection in patients with kidney cancer: when is it indicated?

Authors:  Ganesh S Palapattu; Hyung L Kim; Arie S Belldegrun
Journal:  Rev Urol       Date:  2003

Review 5.  The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.

Authors:  Xu Shi; Dechao Feng; Dengxiong Li; Facai Zhang; Wuran Wei
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

6.  Renal cell carcinoma under 35 years of age: comparison of survival rates for symptomatic and asymptomatic patients.

Authors:  Vahudin Zugor; Swetlana Fridel; Berthold Lausen; Günter E Schott; Reinhard Kühn; Apostolos P Labanaris
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 7.  The rationale and the role of lymph node dissection in renal cell carcinoma.

Authors:  Umberto Capitanio; Bradley C Leibovich
Journal:  World J Urol       Date:  2016-06-30       Impact factor: 4.226

Review 8.  Surgical management of renal cell carcinoma.

Authors:  Laura-Maria Krabbe; Aditya Bagrodia; Vitaly Margulis; Christopher G Wood
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 9.  Long-term outcomes of the surgical management of renal cell carcinoma.

Authors:  John S Lam; Arie S Belldegrun; Allan J Pantuck
Journal:  World J Urol       Date:  2006-02-15       Impact factor: 4.226

10.  Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma.

Authors:  Janine Bacic; Tao Liu; R Houston Thompson; Stephen A Boorjian; Bradley C Leibovich; Dragan Golijanin; Boris Gershman
Journal:  Urology       Date:  2020-03-04       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.